03/09/2026 Phase 3 CERVINO interim analysis shows etentamig significantly improves ORR and PFS in RRMM, with IDMC recommending study unblinding Phase 3 CERVINO interim analysis shows etentamig significantly improves ORR and PFS in RRMM, with IDMC recommending study unblinding (Ref) AbbVie reported positive topline results from the Phase 3 CERVINO trial, demonstrating that etentamig (BCMA x CD3 bispecific T-cell engager) significantly improved response rates and progression-fr